14.08.2018
SHOP APOTHEKE EUROPE N.V. NL0012044747
DGAP-News: Half-year revenues more than doubled: SHOP APOTHEKE EUROPE continues accelerated growth course.
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Half Year Results/Change
in Forecast
Half-year revenues more than doubled: SHOP APOTHEKE EUROPE continues
accelerated growth course.
14.08.2018 / 06:59
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.
Half-year revenues more than doubled: SHOP APOTHEKE EUROPE continues
accelerated growth course.
* Consolidated revenues rose by 103% to EUR 257.2 million during the first
half of the year.
* Consolidated gross earnings increased by 71% to EUR 46.4 million.
* Segment EBITDA margin improved by 1.1% to +0.25% after -0.84% last year.
* EBITDA margin improved from -3.9% to -2.7%
* With revenue growing 120% to EUR 202 million, market share in Germany
was further expanded.
* International revenues rose by 60% to EUR 55 million.
* Number of active customers increased by 27% to 2.8 million as of the
reporting date.
Venlo, the Netherlands, 14 August 2018. SHOP APOTHEKE EUROPE N.V.,
Continental Europe's leading online pharmacy, has continued its rapid growth
course from the beginning of the year. Boosted by the first-time full
consolidation of Europa Apotheek following its acquisition in November 2017,
SHOP APOTHEKE EUROPE increased its revenues by 103% over the first six
months of the current fiscal year to EUR 257.2 million compared to EUR 126.7
million during the corresponding period last year - enabling the company to
further strengthen its market share in Germany and Continental Europe.
Consolidated segment EBITDA improved from EUR -1.1 million a year earlier to
EUR +0.6 million. Relative to revenues, the margin of the consolidated
segment EBITDA improved by +1.1% (from -0.84% in 2017 to +0.25% in the first
half of 2018). The Management Board now expects revenues between EUR 540
million to EUR 570 million for the 2018 fiscal year (previous forecast: EUR
530 million to EUR 560 million) along with significantly improved
profitability. The goal is to achieve a breakeven consolidated EBITDA before
one-time costs (after EUR -8.5 million in 2017) with a challenge of up to
-0.5% based on the consolidated adjusted EBITDA margin, depending in
particular on the fast integration of newly acquired Berlin-based subsidiary
nu3 GmbH.
SHOP APOTHEKE EUROPE increased its consolidated gross earnings by 71%, from
EUR 27.2 million in the first half of 2017 to EUR 46.4 million during the
period under review. In line with expectations, the consolidated gross
margin declined by 3.5% to 18% due to the higher ratio of prescription
medications sold by Europa Apotheek in the Germany segment. A greater share
of products purchased from wholesalers during the first half of 2018 had a
negative effect on earnings. Nonetheless, consolidated segment EBITDA
improved noticeably to +0.6 million compared to EUR -1.1 million a year
earlier.
Administration & sales cost ratio reduced.
First-half 2018 administrative costs adjusted for one-off costs were EUR 7.6
million (2017: EUR 3.9 million); they were reduced to 2.9% relative to
revenues (2017: 3.1%). Selling expenses rose at a lower rate than revenues
as a result of improvements in efficiency and further automation: They
increased by 55% from EUR 29.6 million to EUR 45.8 million. As a result, the
sales cost ratio was 17.8%, substantially lower than a year earlier when it
was 23.4%. This led to a consolidated adjusted EBITDA of EUR -7.0 million
compared to EUR -5 million for the first six months of 2017. The
consolidated EBITDA margin improved from -3.9% last year to -2.7% during the
first half of 2018.
Operational performance indicators further improved; leading online
presence.
The number of orders increased by 45% compared to a year earlier, reaching
4.0 million (H1 2017: 2.8 million) with the size of the average shopping
basket growing around 41%, from EUR 52.7 during the first half of 2017 to
EUR 74.18 in the first six months of 2018. During the second quarter of
2018, the average basket size grew to EUR 74.97. The share of orders placed
by existing customers increased to 81% over the reporting period after 73% a
year earlier. The return rate remained at a minimal level of 0.9% while the
ratio of mobile page visits increased to 55% during the second quarter 2018
and 56% during the first half of 2018. The operational performance
indicators confirm SHOP APOTHEKE EUROPE'S leading online presence.
Segment Germany again posts positive EBITDA.
The integration and consolidation of Europa Apotheek contributed to a
substantial revenue increase during the first half of the year for the
Germany segment. SHOP APOTHEKE EUROPE's largest segment by revenue had
profitable growth of 120% compared to the same period a year earlier.
Revenues climbed to EUR 202.5 million compared to EUR 92.1 million during
the first half of 2017. At the same time, gross earnings were up 78%, from
EUR 19.4 million to EUR 34.6 million year-on-year. Due to a higher ratio of
prescription medications sold as a result of the integration of Europa
Apotheek, the gross margin declined in line with expectations, from 21% in
2017 to 17.1%. Segment EBITDA for the first six months of the year was EUR
3.2 million compared to EUR 2.5 million over the same period last year,
leading to a segment EBITDA margin of 1.6% (2017: 2.7%). This takes into
consideration effects from the new segment structure and from the loss of
other operational income in connection with the integration of Europa
Apotheek as well as the impact of the previously mentioned supply
bottlenecks for several medications. Preparations for the joint market
presence of SHOP APOTHEKE and Europa Apotheek are going ahead as planned and
are expected to generate synergies of EUR 2 - 2.5 million per year starting
in 2019.
Segment International improves EBITDA.
Thanks to a strong rise in the number of orders, the segment International
contributed to the increase in Group revenues: SHOP APOTHEKE EUROPE also
grew its revenues outside of Germany substantially, up 60% to EUR 54.7
million (2017: EUR 34.1 million). The company also further extended its
market leadership in Belgium and Austria. Segment gross earnings rose by 59%
from EUR 7.5 million to EUR 11.9 million during the reporting period with
the gross margin at 21.7%, slightly lower than last year's strong 22.1%.
In line with the share expansion in the company's new markets - Italy,
France and Spain - the segment also had a sharp increase in customer
numbers. Despite the resulting high ratio of orders by new customers - which
require greater acquisition costs - segment EBITDA for the first six months
of 2018 improved to EUR -2.5 million compared to EUR -3.7 million a year
earlier.
Guidance updated following the takeover for nu3 GmbH; further acquisitions
possible.
With the acquisition of nu3 GmbH, which was completed after the reporting
date, SHOP APOTHEKE EUROPE is further strengthening its positioning and
value creation in its European markets: In addition to the expansion of the
product portfolio and the offering of a complementary product offering, the
acquisition generates cross-selling opportunities by addressing new customer
segments. nu3 GmbH already has a presence in key European countries and is
active in the rapidly growing market segment for functional nutritional
products. nu3's high quality portfolio of natural and health products, low
carb products and sports nutrition includes several strong and established
brands.
The Management Board expects a strong second half of the year and is
updating its guidance for the entire 2018 fiscal year: Taking the
consolidation of nu3 GmbH as of July 12, 2018 into account, SHOP APOTHEKE
EUROPE's Management Board now forecasts revenues of EUR 540 million to EUR
570 million for the 2018 fiscal year (previous forecast: EUR 530 million to
EUR 560 million) along with significantly improved results. The goal is to
reach a breakeven consolidated EBITDA before one-time costs (2017: EUR -8.5
million) with a challenge of up to -0.5% based on the consolidated adjusted
EBITDA margin, depending in particular on the fast integration of newly
acquired Berlin-based subsidiary nu3 GmbH.
SHOP APOTHEKE EUROPE intends to continue playing an active role in the
ongoing consolidation of the online pharmacy market, particularly in the
German OTC market. To ensure that the company can respond quickly and
flexibly should interesting business opportunities arise, SHOP APOTHEKE
EUROPE has issued convertible bonds worth EUR 75 million to institutional
investors. Net proceeds from the issue are primarily intended to finance
acquisitions in the OTC segment in Germany to further drive the company's
growth in its most developed market.
2018 FINANCIAL CALENDAR.
30 August 2018 Commerzbank Sector Conference, Frankfurt
24 September Goldman Sachs & Berenberg Conference, Munich
2018
14 November Analyst Day with Publication of Q3 results at
2018 Citibank, London
27 November Berenberg West Coast Conference, San Francisco
2018
3 December Berenberg Pennyhill Conference, London
2018
Consolidated Statement of Profit and Loss
JUNE 30 2018 JUNE 30 2017
EUR 1.000 EUR 1.000
Revenues 257,231 126,707
Cost of sales -210,803 -99,490
Gross earnings 46,428 27,216
Other earnings 8 1,323
Selling & distribution -50,907 -31,389
Administrative costs -8,970 -4,245
Operating income (EBIT) -13,441 -7,094
Interest earnings 77 71
Interest expenses -2,158 -892
Earnings from financial activities -2,081 -821
Earnings before taxes (EBT) -15,522 -7,915
Taxes on income and earnings 593 -209
Period result -14,929 -8,124
To be allocated to shareholders: -14,929 -8,124
SEGMENT INFORMATION H1 2018.
Germany International Consolidated
EUR 1.000 EUR 1.000 EUR 1.000
Revenues 202,486 54,745 257,231
Cost of sales -167,932 -42,872 -210,803
Gross earnings 34,554 11,874 46,428
% of revenues 17.1% 21.7% 18.0%
Other income 0 7 8
Selling & distribution -31,377 -14,419 -45,796
Segment EBITDA 3,178 -2,538 640
Administrative costs -8,068
Adjusted AE -7,592
EBITDA -7,429
Adjusted EBITDA -6,952
Depreciation -6,013
EBIT -13,441
Adjusted EBIT -12,965
Net finance cost and income tax -1,488
Period result -14,929
Adjusted period result -14,453
ABOUT SHOP APOTHEKE EUROPE.
SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in
Continental Europe. With the acquisition of Europa Apotheek Venlo in
November 2017, SHOP APOTHEKE EUROPE significantly extended its European
market leadership with an expanded product range for the whole family in the
areas of OTC, beauty and personal care products as well as prescription
drugs.
SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria,
France, Belgium, Italy, Spain and the Netherlands. In Germany, the
TÜV-certified shop-apotheke.com is the clear market leader. SHOP APOTHEKE
EUROPE delivers a broad range of more than 100,000 original products to over
3 million active customers fast and at attractive prices. In addition, SHOP
APOTHEKE EUROPE provides comprehensive pharmaceutical consulting services.
SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the
Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.
Media contacts.
Trade and popular media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: [email protected]
Financial media:
Thomas Schnorrenberg
Mobile +49 151 46 53 13 17
Email: [email protected]
Investor relations:
Dr. Ulrich Wandel
Phone: +31 77 850 6117
Email: [email protected]
DISCLAIMER.
This release contains statements that relate to future business performance
and future financial performance, as well as to events or developments
pertaining to SHOP APOTHEKE EUROPE, and that may constitute forward-looking
statements. These statements are based on current expectations and
assumptions by SHOP APOTHEKE EUROPE's management, a large number of which
are beyond the control of SHOP APOTHEKE EUROPE. They are therefore subject
to a variety of risks and uncertainties. If these risks and uncertainties
materialize, or the underlying expectations do not materialize or the
assumptions made prove incorrect, actual events, both in a positive and
negative sense, may differ materially from those described or implied in the
forward-looking statements. SHOP APOTHEKE EUROPE undertakes no obligation to
update these forward-looking statements or to correct them in any other than
anticipated development. SHOP APOTHEKE EUROPE also does not intend to do so.
---------------------------------------------------------------------------
14.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Dirk Hartogweg 14
5928 LV Venlo
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: [email protected]
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
713845 14.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
SHOP APOTHEKE EUROPE N.V. ISIN: NL0012044747 können Sie bei EQS abrufen
E-Commerce , A2AR94 , RDC , XETR:RDC